|
gptkbp:instanceOf
|
gptkb:drug
biguanide
oral antidiabetic agent
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
|
|
gptkbp:ATCCode
|
gptkb:A10BX03
|
|
gptkbp:brand
|
gptkb:Starlix
gptkb:Starlixx
|
|
gptkbp:CASNumber
|
gptkb:105816-04-4
|
|
gptkbp:chemicalFormula
|
phenylalanine derivative
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
meglitinides
|
|
gptkbp:eliminationHalfLife
|
1.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C19H27NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nateglinide
|
|
gptkbp:indication
|
improving glycemic control in adults with type 2 diabetes
|
|
gptkbp:KEGGID
|
D01131
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
stimulates insulin secretion
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
CHEMBL1422
3062316
2322110
DB00731
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
dizziness
back pain
upper respiratory tract infection
|
|
gptkbp:synonym
|
gptkb:nateglynide
AY-4166
|
|
gptkbp:UNII
|
Y7JWI6P18Y
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Starlix
|
|
gptkbp:bfsLayer
|
5
|